TriangleDISEASE & TREATMENT SETTING
Multiple Myeloma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Multiple Myeloma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Plasma Cell Neoplasms (Including Multiple Myeloma). Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
35 more-specific settings
Elrexfio: refractory multiple myeloma after prior therapy →Lynozyfic: refractory multiple myeloma after prior therapy →Talvey: refractory multiple myeloma after prior therapy →Zenbexus: multiple myeloma after prior therapy →Darzalex: refractory multiple myeloma after prior therapy →Kyprolis: multiple myeloma after prior therapy →Pomalyst: multiple myeloma after prior therapy →Tecvayli: refractory multiple myeloma after prior therapy →Xpovio: refractory multiple myeloma after prior therapy →Blenrep: refractory multiple myeloma after prior therapy →Farydak: multiple myeloma after prior therapy →Pepaxto: refractory multiple myeloma after prior therapy →Abecma: refractory multiple myeloma after prior therapy →DARZALEX: refractory multiple myeloma after prior therapy →Sarclisa: refractory multiple myeloma after prior therapy →Blenrep: refractory multiple myeloma after prior therapy →Darzalex Faspro: refractory multiple myeloma after prior therapy →XPOVIO: refractory multiple myeloma after prior therapy →TECVAYLI: refractory multiple myeloma after prior therapy →XPOVIO: multiple myeloma after prior therapy →Sarclisa Escena: refractory multiple myeloma after prior therapy →XPOVIO: multiple myeloma after prior therapy →KYPROLIS: refractory multiple myeloma after prior therapy →NINLARO: multiple myeloma after prior therapy →Darzalex Faspro: refractory multiple myeloma after prior therapy →EMPLICITI: multiple myeloma after prior therapy →CARVYKTI: refractory multiple myeloma after prior therapy →KYPROLIS: refractory multiple myeloma after prior therapy →Elrexfio: refractory multiple myeloma after prior therapy →EMPLICITI: multiple myeloma after prior therapy →DARZALEX: refractory multiple myeloma after prior therapy →KYPROLIS: refractory multiple myeloma after prior therapy →Pomalyst: multiple myeloma after prior therapy →advanced Multiple Myeloma →refractory Multiple Myeloma →
Study evidence for this setting
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
Indication-specific source history
2003-05-13 · Velcade (bortezomib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-79e4fa59079280bd
- event date
- 2003-05-13
- event kind
- accelerated-approval
- drug or regimen
- Velcade (bortezomib)
- source indication text
- Multiple myeloma patients who received at least two prior therapies and demontrated disease progression on the last therapy
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-3229a602d58113c944ae
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2005-03-25 · Velcade (bortezomib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-69110589005f0228
- event date
- 2005-03-25
- event kind
- traditional-approval
- drug or regimen
- Velcade (bortezomib)
- source indication text
- Multiple myeloma patients who received at least two prior therapies and demontrated disease progression on the last therapy
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-3229a602d58113c944ae
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2006-05-25 · Thalomid (thalidomide) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-c50fc0716d133337
- event date
- 2006-05-25
- event kind
- accelerated-approval
- drug or regimen
- Thalomid (thalidomide)
- source indication text
- Newly diagnosed multiple myeloma
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-5b7c1b230a7c2c331a79
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2012-07-20 · Kyprolis (carfilzomib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-79f2d1fda630bbb0
- event date
- 2012-07-20
- event kind
- accelerated-approval
- drug or regimen
- Kyprolis (carfilzomib)
- source indication text
- Multiple myeloma after at least 2 prior therapies including bortezomib and an immunomodulatory agent and disease progression on or within 60 days of completion of the last therapy
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-815554ae29b00285d4bf
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2013-02-08 · Pomalyst (pomalidomide) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-8fa3453389aee69a
- event date
- 2013-02-08
- event kind
- accelerated-approval
- drug or regimen
- Pomalyst (pomalidomide)
- source indication text
- Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-fd5b3691571855a5945e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2014-06-19 · Thalomid (thalidomide) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-ea976661b96bf628
- event date
- 2014-06-19
- event kind
- traditional-approval
- drug or regimen
- Thalomid (thalidomide)
- source indication text
- Newly diagnosed multiple myeloma
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-5b7c1b230a7c2c331a79
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2015-02-23 · Farydak (panobinostat) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-59433ae1d05143d2
- event date
- 2015-02-23
- event kind
- accelerated-approval
- drug or regimen
- Farydak (panobinostat)
- source indication text
- In combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-0794f2b7034a9cbac32c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2015-04-23 · Pomalyst (pomalidomide) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-f79fd070aab58e6b
- event date
- 2015-04-23
- event kind
- traditional-approval
- drug or regimen
- Pomalyst (pomalidomide)
- source indication text
- Multiple myeloma after at least 2 prior therapies including lenalidomide and bortezomib and disease progression on or within 60 days of completion of the last therapy
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-fd5b3691571855a5945e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2015-11-16 · Darzalex (daratumumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-439c0d3cb57e6444
- event date
- 2015-11-16
- event kind
- accelerated-approval
- drug or regimen
- Darzalex (daratumumab)
- source indication text
- Multiple myeloma after at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or double refractory to a proteasome inhibitor and an immunomodulatory agent
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-25968884935cc9e78fb3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2016-01-21 · Kyprolis (carfilzomib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-df1332099b8f1db0
- event date
- 2016-01-21
- event kind
- traditional-approval
- drug or regimen
- Kyprolis (carfilzomib)
- source indication text
- Multiple myeloma after at least 2 prior therapies including bortezomib and an immunomodulatory agent and disease progression on or within 60 days of completion of the last therapy
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-815554ae29b00285d4bf
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2016-11-21 · Darzalex (daratumumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-1d5fa345d4d4fed4
- event date
- 2016-11-21
- event kind
- traditional-approval
- drug or regimen
- Darzalex (daratumumab)
- source indication text
- Multiple myeloma after at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or double refractory to a proteasome inhibitor and an immunomodulatory agent
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-25968884935cc9e78fb3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-07-03 · Xpovio (selinexor) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-2c63f4a5e308bfee
- event date
- 2019-07-03
- event kind
- accelerated-approval
- drug or regimen
- Xpovio (selinexor)
- source indication text
- In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b8f6b6d586183413c7e2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-08-05 · Blenrep (belantamab mafodotin-blmf) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-06d462d42578bf83
- event date
- 2020-08-05
- event kind
- accelerated-approval
- drug or regimen
- Blenrep (belantamab mafodotin-blmf)
- source indication text
- Adults patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-84074131ae2e73b04ba7
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-12-18 · Xpovio (selinexor) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-a7a9faa75857a3a7
- event date
- 2020-12-18
- event kind
- traditional-approval
- drug or regimen
- Xpovio (selinexor)
- source indication text
- In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b8f6b6d586183413c7e2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-02-26 · Pepaxto (melphalan flufenamide) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-c2d24abb99c830b6
- event date
- 2021-02-26
- event kind
- accelerated-approval
- drug or regimen
- Pepaxto (melphalan flufenamide)
- source indication text
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-62f2769206d7be686efa
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-03-24 · Farydak (panobinostat) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-42a380df6c85500b
- event date
- 2022-03-24
- event kind
- withdrawal
- drug or regimen
- Farydak (panobinostat)
- source indication text
- In combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior regimens, including BTZ and an immunomodulatory agent.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-0794f2b7034a9cbac32c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-10-25 · Tecvayli (teclistamab-cqyv) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-20487dac283432a9
- event date
- 2022-10-25
- event kind
- accelerated-approval
- drug or regimen
- Tecvayli (teclistamab-cqyv)
- source indication text
- Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-10d01c97e4f62e394410
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-02-06 · Blenrep (belantamab mafodotin-blmf) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-e222e4caf68e16bf
- event date
- 2023-02-06
- event kind
- withdrawal
- drug or regimen
- Blenrep (belantamab mafodotin-blmf)
- source indication text
- Adults patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-84074131ae2e73b04ba7
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-08-09 · Talvey (talquetamab-tgvs) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-77ce88783b2734fc
- event date
- 2023-08-09
- event kind
- accelerated-approval
- drug or regimen
- Talvey (talquetamab-tgvs)
- source indication text
- Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-07e77bdba4e281fb49f5
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-08-14 · Elrexfio (elranatamab-bcmm) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-5ee1fc8706c9b847
- event date
- 2023-08-14
- event kind
- accelerated-approval
- drug or regimen
- Elrexfio (elranatamab-bcmm)
- source indication text
- Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-437c96fec1234e278012
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-02-23 · Pepaxto (melphalan flufenamide) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-66881839382eab89
- event date
- 2024-02-23
- event kind
- withdrawal
- drug or regimen
- Pepaxto (melphalan flufenamide)
- source indication text
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-62f2769206d7be686efa
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-07-02 · Lynozyfic (linvoseltamab-gcpt) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-39ca2886a21209a6
- event date
- 2025-07-02
- event kind
- accelerated-approval
- drug or regimen
- Lynozyfic (linvoseltamab-gcpt)
- source indication text
- Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9d8f489e1fde5734a831
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-07-02 · linvoseltamab-gcpt · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-862be6855fd8b2a6
- event date
- 2025-07-02
- event kind
- approval-notification
- drug or regimen
- linvoseltamab-gcpt
- source indication text
- FDA approved linvoseltamab-gcpt, a bispecific B-cell maturation antigen -directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-20922be08c90e6ba
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-10-23 · belantamab mafodotin-blmf · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-99fb3de89358ef89
- event date
- 2025-10-23
- event kind
- approval-notification
- drug or regimen
- belantamab mafodotin-blmf
- source indication text
- FDA approved belantamab mafodotin-blmf, a B-cell maturation antigen -directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-29d861b96a3e37e4
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-06 · daratumumab and hyaluronidase-fihj · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-b7c3d4e9a1118195
- event date
- 2025-11-06
- event kind
- approval-notification
- drug or regimen
- daratumumab and hyaluronidase-fihj
- source indication text
- FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma .
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-ebc8920f637fe1db
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-01-27 · daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-d182363b441df142
- event date
- 2026-01-27
- event kind
- approval-notification
- drug or regimen
- daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone
- source indication text
- FDA approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant .
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-af9011a2d75e5c91
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-05 · Tecvayli (teclistamab-cqyv) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-06980eba1b1b89d2
- event date
- 2026-03-05
- event kind
- traditional-approval
- drug or regimen
- Tecvayli (teclistamab-cqyv)
- source indication text
- Adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-10d01c97e4f62e394410
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-05 · teclistamab in combination with daratumumab hyaluronidase-fihj · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-8c87e6ae9407b2be
- event date
- 2026-03-05
- event kind
- approval-notification
- drug or regimen
- teclistamab in combination with daratumumab hyaluronidase-fihj
- source indication text
- FDA approved teclistamab in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-b050e96dd06339f0
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-07-09 · isatuximab-irfc · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-f57b03e0c1c0d2cb
- event date
- 2026-07-09
- event kind
- approval-notification
- drug or regimen
- isatuximab-irfc
- source indication text
- FDA approved isatuximab-irfc for subcutaneous injection for multiple myeloma indications. The specific indications approved for Isatuximab-irfc are:
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-99375b4186db616c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-08-13 · Zenbexus (iberdomide) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- fda-51dbb3ec5cbb490b
- event date
- 2026-08-13
- event kind
- accelerated-approval
- drug or regimen
- Zenbexus (iberdomide)
- source indication text
- In combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1b653aa9cbb1875e6d30
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-08-13 · iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- event id
- notice-93c955732caab02e
- event date
- 2026-08-13
- event kind
- approval-notification
- drug or regimen
- iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone
- source indication text
- FDA approved iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
- match phrase
- multiple myeloma
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-9b5c25c72ccbc4de
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- binding id
- ncit-C3242
- source collection
- ncit-concept
- source key
- C3242
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice